Trial Profile

Phase 3 study of dupilumab in the patients with bullous pemphigoid

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Bullous pemphigoid
Focus Registrational; Therapeutic Use

Most Recent Events

31 Oct 2024 According to a Regeneron Pharmaceuticals media release, BP sBLA submission planned for fourth quarter of 2024.
25 Jul 2024 According to a Sanofi media release, data from this study expected in H2 2024 and regulatory submissions to US FDA expected in H1 2025.
06 Feb 2020 Status changed from planning to recruiting, according to a Sanofi media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com